354 related articles for article (PubMed ID: 24318021)
1. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.
Berasain C; Avila MA
J Gastroenterol; 2014 Jan; 49(1):9-23. PubMed ID: 24318021
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor signaling in hepatocellular carcinoma: inflammatory activation and a new intracellular regulatory mechanism.
Berasain C; Nicou A; Garcia-Irigoyen O; Latasa MU; Urtasun R; Elizalde M; Salis F; Perugorría MJ; Prieto J; Recio JA; Corrales FJ; Avila MA
Dig Dis; 2012; 30(5):524-31. PubMed ID: 23108309
[TBL] [Abstract][Full Text] [Related]
3. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.
Bacigalupo ML; Manzi M; Rabinovich GA; Troncoso MF
World J Gastroenterol; 2013 Dec; 19(47):8831-49. PubMed ID: 24379606
[TBL] [Abstract][Full Text] [Related]
4. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system.
Latasa MU; Salis F; Urtasun R; Garcia-Irigoyen O; Elizalde M; Uriarte I; Santamaria M; Feo F; Pascale RM; Prieto J; Berasain C; Avila MA
PLoS One; 2012; 7(12):e52711. PubMed ID: 23285165
[TBL] [Abstract][Full Text] [Related]
5. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
6. EGFR Signaling in Liver Diseases.
Komposch K; Sibilia M
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26729094
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma.
Harada K; Shiota G; Kawasaki H
Liver; 1999 Aug; 19(4):318-25. PubMed ID: 10459631
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in hepatocellular carcinoma.
Bronte F; Bronte G; Cusenza S; Fiorentino E; Rolfo C; Cicero G; Bronte E; Di Marco V; Firenze A; Angarano G; Fontana T; Russo A
Curr Med Chem; 2014; 21(8):966-74. PubMed ID: 23992323
[TBL] [Abstract][Full Text] [Related]
9. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.
Huang P; Xu X; Wang L; Zhu B; Wang X; Xia J
J Cell Mol Med; 2014 Feb; 18(2):218-30. PubMed ID: 24268047
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
11. Amphiregulin: a new growth factor in hepatocarcinogenesis.
Berasain C; Castillo J; Perugorría MJ; Prieto J; Avila MA
Cancer Lett; 2007 Aug; 254(1):30-41. PubMed ID: 17321672
[TBL] [Abstract][Full Text] [Related]
12. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.
Berasain C; Castillo J; Prieto J; Avila MA
Liver Int; 2007 Mar; 27(2):174-85. PubMed ID: 17311611
[TBL] [Abstract][Full Text] [Related]
13. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of tumor necrosis factor-α signaling in hepatocellular carcinoma.
Jang MK; Kim HS; Chung YH
Curr Pharm Des; 2014; 20(17):2799-808. PubMed ID: 23944370
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma.
Giannelli G; Napoli N; Antonaci S
Curr Pharm Des; 2007; 13(32):3301-4. PubMed ID: 18045182
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies.
Wiedmann MW; Mössner J
Curr Cancer Drug Targets; 2011 Jul; 11(6):714-33. PubMed ID: 21599629
[TBL] [Abstract][Full Text] [Related]
19. PGE
Zang S; Ma X; Wu Y; Liu W; Cheng H; Li J; Liu J; Huang A
Hum Pathol; 2017 May; 63():120-127. PubMed ID: 28300577
[TBL] [Abstract][Full Text] [Related]
20. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
